e040e6c8-34e5-44fb-a6f3-c247009fccfc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
- ANGIOGENESIS+0.430
- UV_RESPONSE_DN+0.430
- HEDGEHOG_SIGNALING+0.390
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V2+0.330
- APICAL_JUNCTION+0.290
- MITOTIC_SPINDLE+0.290
- MYOGENESIS+0.270
- IL6_JAK_STAT3_SIGNALING+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- OXIDATIVE_PHOSPHORYLATION-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- PANCREAS_BETA_CELLS-0.390
- INTERFERON_GAMMA_RESPONSE-0.350
- FATTY_ACID_METABOLISM-0.340
- DNA_REPAIR-0.310
- PI3K_AKT_MTOR_SIGNALING-0.300
- PEROXISOME-0.290
- BILE_ACID_METABOLISM-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-8298-01A-11R-2403-07 | — | — | 0.870 |
| 2 | SRR27320698 | — | — | 0.854 |
| 3 | TCGA-CN-5355-01A-01R-1436-07 | — | — | 0.784 |
| 4 | f3781318-56be-4a43-b72d-a6bb65ef9a88 | — | — | 0.768 |
| 5 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.767 |
| 6 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.764 |
| 7 | TCGA-CN-6989-01A-11R-1915-07 | — | — | 0.763 |
| 8 | 21b172a2-72ce-4cfc-b021-cf8c36359feb | — | — | 0.762 |
| 9 | TCGA-CR-7367-01A-11R-2016-07 | — | — | 0.757 |
| 10 | TCGA-98-A539-01A-31R-A262-07 | — | cohortSQ1 | 0.750 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |